Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
Clinical implications of T cell exhaustion for cancer immunotherapy
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
[HTML][HTML] Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …
second-line therapies or that has relapsed after stem-cell transplantation have a poor …
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
CA Jacobson, JC Chavez, AR Sehgal… - The lancet …, 2022 - thelancet.com
Background Most patients with advanced-stage indolent non-Hodgkin lymphoma have
multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric …
multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric …
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …